BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 18, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Jan. 3, 2019
View Archived Issues
Failure of AMPK caused by multiple uremic factors is a key mechanism of energy depletion in CKD
Read More
Localized cell death processes contribute to neurodegeneration
Read More
Epigenetic protein switches function after development
Read More
New HPV vaccine overcomes viral-type specificity
Read More
PIN Pharma presents first-in-human study results for its precision immune stimulant PIN-2
Read More
Medivir patents new MALT1 inhibitors
Read More
Preliminary data announced from phase I study of HPN-424 in patients with prostate cancer
Read More
Eloxx Pharmaceuticals synthesizes compounds for genetic disorders
Read More
Results presented from phase III CASSINI study evaluating rivaroxaban thromboprophylaxis
Read More
Institute of Materia Medica of Beijing presents compounds for cough
Read More
Deciphera Pharmaceuticals reports preliminary data from its ongoing phase I study of DCC-3014
Read More
Merck & Co. discloses muscarinic M4 receptor PAMs
Read More
Boehringer Ingelheim patents VNN1 inhibitors
Read More
FDA approves Sprycel with chemotherapy for pediatric Ph+ ALL
Read More
Propanc Biopharma enters collaboration with University of Jaen
Read More
Phase II trial of AEVI-001 in pediatric ADHD does not meet primary endpoint
Read More
Adlai and Merck & Co. enter clinical trial collaboration to study AN-0025 with Keytruda
Read More
Chinese NMPA accepts IND for Asceltis Pharma's third HCV drug ASC-21
Read More
Flexion initiates phase III study of Zilretta for hip osteoarthritis
Read More
TIM-3/Gal-9 autocrine signaling loop unveiled as therapeutic target for AML
Read More
FDA accepts IND for phase Ib study of DM-199 for diabetes-related CKD
Read More
U.S. patients to join global phase II trial of mavrilimumab for giant cell arteritis
Read More